Pfizer receives FDA approval for BESPONSA® (inotuzumab ozogamicin)
Pfizer announced the FDA has approved BESPONSA® (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. BESPONSA was reviewed and approved under the FDA’s Breakthrough Therapy designation and Priority Review programs. August 17, 2017